摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one | 128-62-1

中文名称
——
中文别名
——
英文名称
(S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one
英文别名
Narcotin;(-)-α-narcotine;narcotine;noscapine;opianine;(3S)-6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one;(3S)-6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-2-benzofuran-1-one
(<i>S</i>)-6,7-dimethoxy-3-((<i>R</i>)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-<i>g</i>]isoquinolin-5-yl)-3<i>H</i>-isobenzofuran-1-one化学式
CAS
128-62-1;3860-46-6;6035-40-1;10421-76-8;35933-62-1;35933-63-2;35933-64-3;85280-20-2
化学式
C22H23NO7
mdl
——
分子量
413.427
InChiKey
AKNNEGZIBPJZJG-ZVAWYAOSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    174-176 °C(lit.)
  • 比旋光度:
    -200 º (c=1 in chloroform)
  • 沸点:
    532.6°C (rough estimate)
  • 密度:
    1.395
  • 溶解度:
    几乎不溶于水,溶于丙酮,微溶于乙醇(96%)。溶于强酸;用水稀释溶液时,碱可能会沉淀。

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    75.7
  • 氢给体数:
    0
  • 氢受体数:
    8

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    Xn
  • 安全说明:
    S24/25
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 海关编码:
    29329990
  • 危险品运输编号:
    UN 1544
  • RTECS号:
    RD2625000
  • 包装等级:
    III
  • 危险类别:
    6.1(b)

SDS

SDS:b23071d7042474d961031ca400044723
查看

制备方法与用途

生物活性

Noscapine ((S,R)-Noscapine) 是一种具有口服活性的苯酞异喹啉生物碱,具有强效镇咳作用。它通过激活 sigma 阿片类受体 (sigma opioid receptors) 发挥镇咳作用,并且是一种非竞争性 Bradykinin 抑制剂。Noscapine 破坏微管动力学,导致细胞有丝分裂停滞和凋亡。此外,Noscapine 还具有抗癌、神经保护及抗炎活性,并能够穿越血脑屏障。

靶点
  • Sigma opioid receptors
  • Bradykinin
  • Apoptosis
体外研究

在体外研究中,诺斯卡平(0-1000 μM;0-96小时)处理大鼠 C6 肿瘤胶质细胞时表现出剂量和时间依赖性的细胞活力抑制作用。诺斯卡平在72小时时的半数抑制浓度 (IC50) 为250 μM。诺斯卡平暴露可引起S期异常重入,增加有丝分裂停滞,并导致 DNA 过度积累。Cylindromatosis 增强了诺斯卡平诱导的有丝分裂停滞和凋亡能力。Cylindromatosis 促进了微管聚合并增强了诺斯卡平与微管的结合。

实验项目
细胞系 大鼠 C6 肿瘤胶质细胞
浓度 (μM) 0, 0.1, 1, 2, 10, 50, 100, 1000
培养时间 (小时) 0, 12, 24, 48, 72, 96
结果 以剂量和时间为依赖的方式抑制大鼠 C6 肿瘤胶质细胞的活力
体内研究

口服给药(300 mg/kg;每日一次,持续15天)诺斯卡平治疗可显著减少裸小鼠 (nu/nu) 的肿瘤生长。这些动物在8周龄时被注射了大鼠 C6 肿瘤胶质细胞。

实验项目
动物模型 裸小鼠 (nu/nu),8周龄,注射大鼠 C6 肿瘤胶质细胞
用药剂量 (mg/kg) 300
给药方式 口服灌胃;每日一次,持续15天
结果 显著减少了肿瘤体积
化学性质

Noscapine 是一种无色结晶性粉末或有光泽的棱柱状或片状结晶,无臭,无味。它几乎不溶于水,微溶于乙醇与乙醚,并且能够溶解在氯仿中。

用途

诺斯卡平是一种支气管解痉性镇咳药。

文献信息

  • CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
    申请人:Anji Pharma (US) LLC
    公开号:EP2661266B1
    公开(公告)日:2020-09-16
  • JPS59161315A
    申请人:——
    公开号:JPS59161315A
    公开(公告)日:1984-09-12
  • Chemosensory Receptor Ligand-Based Therapies
    申请人:BARON Alain D.
    公开号:US20120177730A1
    公开(公告)日:2012-07-12
    Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
  • US9050292B2
    申请人:——
    公开号:US9050292B2
    公开(公告)日:2015-06-09
  • US9463170B2
    申请人:——
    公开号:US9463170B2
    公开(公告)日:2016-10-11
查看更多

同类化合物

阿托喹啉 那可汀 那可丁N-氧化物 诺司卡品 盐酸盐 水合物 细果角茴香碱 紫堇明 盐酸那可丁一水合物 盐酸诺格考平 盐酸白毛莨碱 曲托喹啉 山缘草定碱 咖喏定 北美黄连碱 [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 [6S,(+)]-6-[(1S)-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉-1-基]呋喃并[3,4-e]-1,3-苯并二氧戊环-8(6H)-酮 7-氨基-4,5,6-三乙氧基-3-(6,7,8-三甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基)-3H-2-苯并呋喃-1-酮 7-O-去甲基alpha-那可丁 6,7-二甲氧基-3-[(5R)-4-甲氧基-6-甲基-7,8-二氢-5H-[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-3H-2-苯并呋喃-1-酮 3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 (3S)-6,7-二甲氧基-3-[(5S)-6-甲基-5,6,7,8-四氢[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-2-苯并呋喃-1(3H)-酮 (3S)-3-[(1R)-6,7-二羟基-8-甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基]-6,7-二甲氧基-3H-2-苯并呋喃-1-酮 (-)-荷苞牡丹碱甲溴化物 (-)-荷苞牡丹碱 (-)-荷包牡丹碱甲溴化物 (-)-荷包牡丹碱甲氯化物 (-)-紫堇明 (+)-荷苞牡丹碱甲氯化物 (+)-荷包牡丹碱 hydrastidine isohydrastidine 5,9-bis-(4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (S,R)-9-bromo noscapine (S)-3-{(R)-9-[(2-chloro-acetylamino)-methyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-6,7-dimethoxy-phthalide (S)-6,7-dimethoxy-3-{(R)-4-methoxy-6-methyl-9-[(2-morpholino-acetylamino)-methyl]-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-phthalide (R)-5-((S)-4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline-9-carboxylic acid methyl ester 4-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid ethyl 4-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate N-(3-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)phenyl)acetamide (S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-7-hydroxy-6-methoxyisobenzofuran-1(3H)-one ethyl 2-chloro-5-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate 3-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)propane-1-sulfonic acid 4-(((S)-5-methoxy-1-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid (3S)-6,7-dimethoxy-3-((5R)-4-methoxy-6-methyl-9-(4-vinylphenyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one (R)-5-((S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline-9-carbaldehyde N-desmethyl-N-carbethoxynarcotine (S)-3-((R)-9-bromo-4-methoxy-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxyisobenzofuran-1(3H)-one 9-Fluoro-Noscapine 9-Nitro-Noscapine 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one